Biolife solutions to acquire sexton biotechnologies to expand cell and gene therapy tools portfolio

Bothell, wash., aug. 9, 2021 /prnewswire/ --  biolife solutions , inc. (nasdaq: blfs) ("biolife" or the "company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has entered into a definitive agreement to acquire all remaining outstanding shares of privately held sexton biotechnologies, inc., that it does not currently own, for $24.0 million, in consideration for 506,382 newly issued shares of biolife common stock.
BLFS Ratings Summary
BLFS Quant Ranking